Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

For Consumers

Alternative dosing regimen for Reyataz (atazanavir) for treatment-naïve patients who can take ritonavir

On September 30, 2008, FDA approved an alternative dosing regimen for Reyataz (atazanavir) for HIV-1 infected treatment-naïve patients who can take ritonavir. The recommended dosage is Reyataz 300 mg with ritonavir 100 mg once daily for treatment-naïve patients. Revisions with respect to the new dosing regimen in treatment-naïve patients were added to the package insert. Other minor revisions were made throughout the label.

The revised label can be found at

Richard Klein
Office of Special Health Issues
Food and Drug Administration

Kimberly Struble
Division of Antiviral Drug Products
Food and Drug Administration

Page Last Updated: 08/13/2014
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.